The Safety and Efficacy of Ibrutinib in Refractory/Relapsed Autoimmune Hemolytic Anemia

Inclusion Criteria: * ECOG ≤ 3 * Age from 6 to 70. * Diagnosed with WAIHA or MAIHA. * Meets the criteria of relapsed / refractory AIHA. * Meets the criteria of DAT-negative AIHA without any other inherited or acquired hemolytic diseases, and previously treated effectively with glucocorticoids and rituximab. * Signed informed consent. * Organs in good function. Exclusion Criteria: * Nursing woman * Active bacterial, virus, fungal or parasitic infection, including HIV infection, HbsAg and HBV DNA positive, HCV DNA positive, etc. * Diagnosed with cold agglutinin disease or cold agglutinin syndrome or paroxysmal cold hemoglobinuria. * Secondary AIHA caused by drugs or infection. * Received rituximab in 8 weeks before enrollment. * Previously received treatment with BTK inhibitor. * Previously received organ or stem cell transplantation. * Have a history of thrombosis or organ infarction. * Diagnosed with an active stage of connective tissue disease. * Have a history of lymphoproliferative tumors or any other malignant tumors. * Have other inherited or acquired hemolytic diseases. * Received low-molecular-weight heparin or warfarin within 1 week before enrollment or during the Ibrutinib treatment. * Received CYP3A4 Enzyme Inhibitors or Inducers within 1 week before enrollment or during the Ibrutinib treatment. * Have a history of mental illness. * Inability to understand or to follow study procedures.